H&R Block to Participate in the Barclays Global Financial Services Conference
03 sept. 2024 16h05 HE
|
HRB Tax Group, Inc.
KANSAS CITY, Mo., Sept. 03, 2024 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) today announced that Tony Bowen, Chief Financial Officer, and Michaella Gallina, Vice President, Investor...
Public Art Abu Dhabi Launches with the Unveiling of WAVE Media Art Installation
21 mars 2023 06h57 HE
|
Public Art Abu Dhabi
The Department of Culture and Tourism – Abu Dhabi’s new initiative is part of its ongoing commitment to commissioning public art for the emirate Three major long-term elements include Public Art Abu...
SimplyRFID Unveils RFID Inventory for Shopify at the NRF Big Show
13 janv. 2023 12h00 HE
|
SimplyRFiD
NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) -- SimplyRFID's Wave 3.3.9 releases on January 20, 2023 and can be previewed at the NRF Big Show this week (Jan. 15-17) at booth #4246 in the Javits Center,...
Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
09 févr. 2022 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
10 nov. 2021 07h30 HE
|
Wave Life Sciences USA, Inc.
Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing Optimized AIMers for AATD program demonstrate potent, highly...
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
08 nov. 2021 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy
29 sept. 2021 08h30 HE
|
Wave Life Sciences USA, Inc.
Trial is expected to enroll 15 boys with DMD amenable to exon 53 skipping First systemically administered therapeutic candidate with PN backbone chemistry modifications to be assessed in the clinic ...
Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
28 sept. 2021 16h05 HE
|
Wave Life Sciences USA, Inc.
Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months Chemistry optimization yields a four-fold increase over PBS control in AAT...
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
22 sept. 2021 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
D2L INTRODUCES D2L WAVE—THE FUTURE OF UPSKILLING AND RESKILLING
07 juil. 2021 09h52 HE
|
D2L
Kitchener, Waterloo, July 07, 2021 (GLOBE NEWSWIRE) -- Global learning technology leader D2L today announced the launch of D2L Wave, a bold new approach to professional development that makes it...